A Meeting for iPS !
Dates: July 2 (Wed)- 4 (Fri), 2008
Venue: Tokyo Big Sight, Japan
Organised by: Reed Exhibitions Japan Ltd
Special Feature: Worldwide Attention on the iPS Cells
-The Unmeasureable Possibilities of iPS Cells-
Medical transportation, such as spinal cord and heart transportation is carrying serious issues
concerning lack of donors. Of which, the heart transportation is facing with the most severe
problem, since it has to rely on brain death patients. For example, in Japan, there are about
2,000 patients waiting to have cardiac transportation, however only 50 have been put to
practice. ※ To overcome this donor issues, “regenerative medical techniques”, which is to
implant cells and tissues from human hands, have been making its way to the approach. ES
cell (embryo-stem cell) had been the card to overcome this donor issues.
However, ES cell still have not been put to practice even though 10 years have passed since its
creation. This is because it contains two problems; ethical and rejection response problems.
In order to make ES cell, there is a need to destroy human embryos, which makes it relevant
for ethical considerations to be discussed. In addition, rejection of the patient occurs during
the transplantation, which makes it difficult to put ES cell into practice.
Under these circumstances, Director, Center for iPS cell Research and Application,
Professor, Institute for Frontier Medical Sciences, Kyoto University, Dr. Shinya
Yamanaka succeeded in creating iPS Cell from a mouse, and the next year completed making
human iPS Cell. The technologies to develop iPS cells are expected to open a new horizon, as
it clears both ethical and rejection response problems. Doctors will be able to produce
replacement cells and tissues from patients’ own cells that will not be rejected by the immune
system when transplanted. The technologies also clear ethical problems, as iPS cells can be
produced without destroying human embryos.
The application of iPS Cell is being counted on worldwide for its use. The search for the
possibilities, challenges, and its application continues.
※Newton June issue 2008
【BIO FORUM】
iPS Cell Research and Application Frontlines July 3rd (Thurs) 10:30-12:00
‘Perspective of iPS Cells’
Director, Center for iPS cell Research and Application, Professor, Institute for Frontier Medical
Sciences, Kyoto University, Dr. Shinya Yamanaka
A team at Kyoto University has succeeded in culturing iPS (induced pluripotent stem) cells that
possess ES (embryo-stem) equivalent capability by inducing a few DNAs to adult human skin
fibroblasts. The ability to produce iPS cells from a patient him/herself would be a valuablemethod in drug discovery and cellular transplantation therapy.
‘Application of Human iPS Cell Technology in Drug Discovery’
Chief Scientific Officer, iZumi Bio, Inc. (Former Operating Officer, Head of Research Center,
Bayer Yakuhin & Head of Therapeutic Research Group Regenerative Medicine, Global Drug
Discovery, Bayer Schering Pharma), Dr. Kazuhiro Sakurada
The human iPS (induced pluripotent stem) cell technology has potential applications at the
various stages of drug discovery process, such as the formulation of new therapy concepts,
pharmacologically-based drug selection methodologies, and the creation of clinical protocols.
The lecture will focus on the technological applications of iPS cells to drug discovery.
搜索更多相关主题的帖子:
Meeting iPS
